INVA at a glance
Innoviva, Inc. (INVA, SEC CIK 1080014) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as August 24, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Innoviva, Inc. (INVA) reported revenue of $411.3 million (up 14.7% from FY2024) and net income of $271.2 million. Diluted EPS was $3.30.
- As of June 30, 2026, 31 institutional investment managers tracked by SignalX reported holding Innoviva, Inc. (INVA) shares worth $985.7 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $411.3M
- +14.7% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 31 funds
- $985.7M · +2 vs prior quarter
- Latest 8-K
- Aug 5, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: diversified biopharmaceutical company with royalties portfolio plus critical care and infectious disease operating platform (Innoviva Specialty Therapeutics)
- New products launched: XACDURO® (2023), ZEVTERA® (Q3 2025), and FDA approval of NUZOLVENCE® (Dec 2025) for infectious diseases
- Strategic shift: transformation from pure-play royalty business to diversified biopharma with fast-growing, differentiated operating platform
- Notable metric: XACDURO® Phase 3 ATTACK trial showed 19.0% mortality vs 32.3% for colistin; approved in US (2023) and China (2024)
- Unusual fact: XACDURO® named preferred treatment for carbapenem-resistant Acinetobacter baumannii in 2024 IDSA guidelines
Risk Factors
- FDA approval of NUZOLVENCE® in Dec 2025, with commercialization planned in H2 2026, regulatory risk around market launch and adoption timing
- Pricing pressures in U.S. caused 2% decline in royalty revenue to $236.5M in 2025, signaling macroeconomic risk on revenue from GSK royalty portfolio
- Supply vulnerability from Zai Lab interim supply agreement for XACDURO® ex-U.S. sales, accounting for significant 218% YoY increase to $40.9M
- Competition risk from established respiratory products RELVAR®/BREO® and ANORO® ELLIPTA® partnered with GSK, with royalties tiered 15% up to $3B sales then 5%
- $300M capital locked in ISP Fund with Sarissa Capital as advisor and withdrawal restrictions, creating financial liquidity and concentration risk until April 2026 distributions
Management Discussion & Analysis
- Revenue details and YoY change not disclosed in provided MD&A excerpt
- Cash flow, buybacks, dividends, capex information not provided
- Forward-looking statements referenced with risks, no specific guidance or outlook given
AI summary of the INVA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Q2 revenue $119.6M, up 19% YoY from $100.3M
- Product sales $51.8M, up 46% YoY; XACDURO strongest growth at 46% overall
- Net royalty revenue $56.3M vs $63.9M YoY, down 12% amid U.S. pricing pressures
- Net loss $83.4M, driven by $161.0M unfavorable investment fair-value changes
- Cash $570.4M; Q2 share repurchases $31.4M and strategic portfolio commitments $55.0M
Risk Factors
- Risk Factors section not provided in submitted filing text
- Share-repurchase activity: 1,403,247 shares bought for $31.4 million during the quarter
- Capital-allocation risk: repurchases reduced remaining authorization to $68,595,263
- Debt risk: 2.125% convertible senior notes due 2028 disclosed as outstanding debt instrument
AI summary of the INVA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- 8-K Item 2.02 furnishes Exhibit 99.1 under Regulation FD, likely containing Innoviva’s fiscal-year 2026 results
- Information not deemed filed under Exchange Act Section 18, limiting liability and incorporation-by-reference consequences
Item EX-99.1: Item EX-99.1
- Q2 revenue $119.6M, up 19% year over year, led by net product sales of $51.8M, up 46%
- IST U.S. sales $36.6M, up 26%, supporting management’s 2026 target of at least $150M
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Derek Small and Mark DiPaolo resigned May 12 to focus on Syndeio BioSciences, where Innoviva has invested and expects continued support
- Departures unrelated to disagreements, reducing concern over governance or strategy disputes
Item 2.02: Results of Operations and Financial Condition
- Exhibit 99.1 furnished with the 8-K, covering Innoviva’s fiscal year 2026 results
- Information not deemed “filed” under Exchange Act Section 18, limiting associated liability
AI summaries of INVA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for INVA
Don't miss the next INVA filing
- Alerts as it files. A push when INVA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut INVA, by share count.
- Ask anything. An AI agent that reads every INVA filing and answers with sources.
INVA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Basso Stephen | F | Aug 20, 2026 | 558 | $21.00 |
| Raifeld Pavel | F | Aug 20, 2026 | 1,130 | $21.00 |
| Zhen Marianne | F | Aug 20, 2026 | 1,127 | $21.00 |
| Basso Stephen | F | May 20, 2026 | 559 | $22.24 |
| Raifeld Pavel | F | May 20, 2026 | 1,130 | $22.24 |
| Zhen Marianne | F | May 20, 2026 | 1,127 | $22.24 |
| Linden Josephine | A | May 18, 2026 | 5,733 | - |
| Linden Josephine | A | May 18, 2026 | 9,166 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $358.7M | $411.3M |
| Gross Profit | $246.0M | $296.2M | $307.7M |
| Operating Income | - | $166.9M | $163.7M |
| Net Income | - | $23.4M | $271.2M |
| Gross Margin | - | 82.6% | 74.8% |
| Op. Margin | - | 46.5% | 39.8% |
| Net Margin | - | 6.5% | 65.9% |
| Balance Sheet | |||
| Total Assets | - | $1.3B | $1.6B |
| Equity | - | $691.2M | $1.2B |
| ROE | - | 3.4% | 23.1% |
| Per Share | |||
| EPS | $2.20 | $0.36 | $3.30 |
| Cash Flow | |||
| Operating CF | - | $188.7M | $196.9M |
| CapEx | - | $270K | $1.1M |
Source: XBRL data in Innoviva, Inc. (INVA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate INVA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 31 | $985.7M |
| Q1 2026 | 29 | $1.01B |
| Q4 2025 | 27 | $808.8M |
| Q3 2025 | 28 | $767.8M |
| Q2 2025 | 29 | $870.7M |
| Q1 2025 | 25 | $598.5M |
| Q4 2024 | 21 | $473.5M |
| Q3 2024 | 19 | $452.5M |
- Millennium Management+261.7K (+11%)
- BlackRock+247.4K (+2%)
- State Street Corp+207.6K (+7%)
- Prudential Financial+59.5K (+44%)
- Dimensional Fund Advisors+57.6K (+1%)
- Two Sigma Investments−451.5K (-30%)
- JPMorgan Chase & Co−207.2K (-59%)
- Invesco Ltd−171.6K (-19%)
- Morgan Stanley−89.9K (-7%)
- D.E. Shaw & Co−82.6K (-33%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 209 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
INVA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Jul 31, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 8-K | May 18, 2026 | - | Analysis | |
| 4 | May 6, 2026 | - | - | |
| 4 | May 6, 2026 | - | - | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 4 | May 6, 2026 | - | - | |
| 4 | May 6, 2026 | - | - | |
| 4 | May 6, 2026 | - | - | |
| 4 | May 6, 2026 | - | - | |
| 8-K | May 6, 2026 | - | Analysis | |
| 4 | May 6, 2026 | - | - | |
| 8-K | May 4, 2026 | - | Analysis | - |
| SC 13G | Apr 29, 2026 | - | - | |
| 8-K | Feb 25, 2026 | - | Analysis | - |
| 10-K | Feb 25, 2026 | Dec 31, 2025 | Analysis | |
| 4 | Feb 24, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
INVA SEC filings: frequently asked questions
Which institutions hold INVA stock?
As of June 30, 2026, the largest Innoviva, Inc. (INVA) holders among the 13F filers tracked by SignalX were BlackRock ($262.4 million), Dimensional Fund Advisors ($102.1 million), Vanguard Portfolio Management LLC ($95.8 million), Renaissance Technologies LLC ($91.7 million), State Street Corp ($74.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was INVA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Innoviva, Inc. (INVA) reported revenue of $411.3 million (up 14.7% from FY2024) and net income of $271.2 million. Diluted EPS was $3.30. The figures come from the XBRL data in the 10-K.
What are the main risks in INVA's latest 10-K?
In the 10-K filed February 25, 2026, Innoviva, Inc. (INVA) flagged: FDA approval of NUZOLVENCE® in Dec 2025, with commercialization planned in H2 2026, regulatory risk around market launch and adoption timing. Pricing pressures in U.S. caused 2% decline in royalty revenue to $236.5M in 2025, signaling macroeconomic risk on revenue from GSK royalty portfolio. (AI summary of the Risk Factors section.)
What did INVA report in its latest 8-K?
Innoviva, Inc. (INVA) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). 8-K Item 2.02 furnishes Exhibit 99.1 under Regulation FD, likely containing Innoviva’s fiscal-year 2026 results.
What are the latest INVA SEC filings?
Innoviva, Inc. (INVA) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on August 24, 2026.
What is INVA's SEC CIK number?
Innoviva, Inc. (INVA)'s SEC Central Index Key (CIK) is 1080014. EDGAR lists every INVA filing under that number.
Ask anything about INVA
The research agent reads INVA's filings, financials, insider trades and 13F holders, then answers with sources.